Serious concerns on the inability of FDG-PET in excluding residual viable lymphoma

Hugo J. A. Adams; Thomas C. Kwee

doi:10.1007/s00277-018-3244-6

Serious concerns on the inability of FDG-PET in excluding residual viable lymphoma

Hugo J. A. Adams^*, Thomas C. Kwee

^*Corresponding author for this work

Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE)

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

1 Citation (Scopus)

38 Downloads (Pure)

Original language	English
Pages (from-to)	915-916
Number of pages	2
Journal	Annals of Hematology
Volume	97
Issue number	5
DOIs	https://doi.org/10.1007/s00277-018-3244-6
Publication status	Published - May-2018

Keywords

RESPONSE-ADAPTED THERAPY
HODGKIN LYMPHOMA
TRIAL
SCAN

Access to Document

10.1007/s00277-018-3244-6

Serious concerns on the inability of FDG-PETFinal publisher's version, 302 KBLicence: Taverne

Handle.net

Persistent link

Cite this

@article{2cd004a92b144548b94f2a13d30e03fa,

title = "Serious concerns on the inability of FDG-PET in excluding residual viable lymphoma",

keywords = "RESPONSE-ADAPTED THERAPY, HODGKIN LYMPHOMA, TRIAL, SCAN",

author = "Adams, {Hugo J. A.} and Kwee, {Thomas C.}",

year = "2018",

month = may,

doi = "10.1007/s00277-018-3244-6",

language = "English",

volume = "97",

pages = "915--916",

journal = "Annals of Hematology",

issn = "0939-5555",

publisher = "Springer",

number = "5",

}

TY - JOUR

T1 - Serious concerns on the inability of FDG-PET in excluding residual viable lymphoma

AU - Adams, Hugo J. A.

AU - Kwee, Thomas C.

PY - 2018/5

Y1 - 2018/5

KW - RESPONSE-ADAPTED THERAPY

KW - HODGKIN LYMPHOMA

KW - TRIAL

KW - SCAN

U2 - 10.1007/s00277-018-3244-6

DO - 10.1007/s00277-018-3244-6

M3 - Comment/Letter to the editor

SN - 0939-5555

VL - 97

SP - 915

EP - 916

JO - Annals of Hematology

JF - Annals of Hematology

IS - 5

ER -